ソース:[1] Teva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for Emrusolmin (https://finance.yahoo.com/news/teva-pharmaceu ...)[2] Teva's Fast Track Designation for Emrusolmin in MSA: Strategic Pipeline Differentiation and Financial Recovery in a High-Risk Neurology Space - AInvest (https://vertexaisearch.cloud.google.com/groun ...)[3] Teva Pharmaceuticals' Emrusolmin Receives FDA Fast Track Designation for MSA Treatment Amidst Mixed Financial Health and Competitive Landscape - AInvest (https://vertexaisearch.cloud.google.com/groun ...)